Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

This editorial highlights the significant clinical challenges and poor outcomes faced by patients with secondary AML after prior hypomethylating agent therapy (HMA-sAML), underscoring the urgent need for novel treatments. The authors emphasize that current standard therapies remain inadequate, calling for clinical trials tailored specifically to address the unique biological complexity and therapeutic resistance observed in this patient population

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11990110PMC
http://dx.doi.org/10.1002/cncr.35838DOI Listing

Publication Analysis

Top Keywords

second status
4
status quo
4
quo secondary
4
secondary acute
4
acute myeloid
4
myeloid leukemia
4
leukemia hypomethylating
4
hypomethylating agents
4
agents editorial
4
editorial highlights
4

Similar Publications

Aim: To assess whether the Mini-Mental State Examination, second edition (MMSE-2), scores were associated with the category of functional independence of nursing-home residents and the level of accommodation services they received.

Methods: This cross-sectional study enrolled 248 participants older than 65 residing in five county-owned nursing homes in the city of Zagreb from 2017 to 2019. Cognitive status was assessed with the standard version of the MMSE-2, and the level of functional independence with the modified Barthel scale index.

View Article and Find Full Text PDF

Background: Dengue virus (DENV) is a major global health challenge, causing over 7.6 million reported cases in 2024. Neutralizing monoclonal antibodies (NmAbs) have emerged as promising therapeutics to address the limitations of vaccines and lack of antivirals, but their development is complicated by viral diversity, "breathing" dynamics, and antibody-dependent enhancement (ADE).

View Article and Find Full Text PDF

Background: Relapsed or refractory cases of pediatric acute myeloid leukemia (AML) have poor outcomes despite advancements in chemotherapy and hematopoietic stem cell transplantation (HSCT). While a second HSCT is often a salvage option, its outcomes vary widely, and prognostic factors remain unclear.

Objectives: This study aimed to evaluate outcomes and identify prognostic factors in pediatric patients with AML who underwent multiple HSCTs.

View Article and Find Full Text PDF

Single-Cell RNA Sequencing Reveals Potential Mechanism of RUNX3 Reshaping Tumor Microenvironment in Non-small-cell Lung Cancer.

Ann Surg Oncol

September 2025

Department of Thoracic Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China.

Background: RUNX3 acts as a tumor suppressor gene in non-small-cell lung cancer (NSCLC), yet its specific biological mechanism is still unclear. This study aimed to uncover tumor microenvironment (TME) changes in NSCLC with varying RUNX3 expression statuses through single-cell RNA sequencing.

Patients And Methods: In total, seven patients with NSCLC with detailed pathological data were involved, with three both paracancerous and cancerous tissue samples.

View Article and Find Full Text PDF